Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

ClinicalTrials.gov ID: NCT05416307

Public ClinicalTrials.gov record NCT05416307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.

Study identification

NCT ID: NCT05416307
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Electra Therapeutics Inc.; Industry
Enrollment: 156 participants

Conditions and interventions

Conditions

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Interventions

ELA026 Drug

Drug

Eligibility (public fields only)

Age range: 6 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 19, 2022 (Actual)
Primary completion: Mar 2028 (Estimated)
Completion: Mar 2030 (Estimated)
Last update posted: Oct 13, 2026

2022 – 2030

United States locations

U.S. sites: 19
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham School of Medicine	Birmingham	Alabama	35233	Recruiting
Phoenix Children's Hospital	Phoenix	Arizona	85016	Completed
University of California, Los Angeles	Los Angeles	California	90095	Completed
MedStar Georgetown University Hospital	Washington D.C.	District of Columbia	20007	Recruiting
Johns Hopkins All Children's Hospital	St. Petersburg	Florida	33701	Recruiting
Children's Healthcare of Atlanta - Center for Advanced Pediatrics	Atlanta	Georgia	30322	Recruiting
Emory University	Atlanta	Georgia	30322	Recruiting
National Institute of Allergy and Infectious Diseases (NIAID)	Rockville	Maryland	20892	Recruiting
Columbia University	New York	New York	10032	Recruiting
Cornell University	New York	New York	10065	Recruiting
Hackensack University Medical Center	New York	New York	10065	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Cleveland Clinic Main Campus	Cleveland	Ohio	44195	Recruiting
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
Texas Children's Hospital	Houston	Texas	77030	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05416307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 31, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05416307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →